Intravenous Immunoglobulin (IVIg) Market Size & Share 2026-2035

Intravenous Immunoglobulin Market Size

The global intravenous immunoglobulin market was estimated at USD 13.3 billion in 2025. The market is expected to grow from USD 14.2 billion in 2026 to USD 25.6 billion in 2035, growing at a CAGR of 6.8% during the forecast period, according to the latest report published by Global Market Insights Inc.

One of the key drivers for growth in the intravenous immunoglobulin market is the increasing incidence of immunodeficiency disorders, both primary and secondary.  For example, as per the NIH, over 6 million people are affected by primary immunodeficiency disorders globally. More than 430 different primary immunodeficiencies or primary immunodeficiency diseases (PIDs) have been described, caused by inherited defects in one or more components of the immune system. With advances in diagnostic technologies and enhanced awareness, an increasing number of patients are being diagnosed with conditions such as chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). These conditions necessitate the use of immunoglobulin treatment to avoid infections and control symptoms, substantially driving the steady demand for IV immunoglobulins.
 

Intravenous immunoglobulins (IVIg) are sterile preparations of concentrated antibodies derived from pooled human plasma and administered through intravenous infusion. They provide passive immunity by providing the body with ready-made antibodies that can be used to combat infections and help to regulate the immune response by neutralizing harmful pathogens. IVIg has been used extensively in the treatment of primary and secondary immunodeficiency, autoimmune, and inflammatory conditions, as well as certain neurological disorders.
 

Major players in the Intravenous immunoglobulin (IVIg) market include CSL Behring, Takeda Pharmaceutical Company, Grifols, Octapharma, and Kedrion. These companies dominate global supply through extensive plasma collection networks, large-scale fractionation facilities, and strong distribution capabilities. Their continuous investments in expanding plasma collection capacity, improving purification technologies, and securing regulatory approvals directly influence product availability and pricing, thereby shaping overall market growth.
 

The IV immunoglobulin market witnessed steady growth, growing from USD 10.8 billion in 2022 to USD 12.5 billion in 2025. One of the major trends that has been observed during this period is the continuous expansion of plasma collection and fractionation capacities by major companies to meet the growing demand in the global market. In addition, the increasing use of IVIg in the treatment of immunodeficiency, autoimmune, and neurological disorders has also contributed to the growth of the market.
 

There are five main classes of immunoglobulins that include IgG, IgA, IgM, IgE, and IgD, each with distinct functions in immune defense. They play a critical role in the body’s defense against infection and diseases by recognizing and binding to specific antigens on the surface of these invaders, thereby making them susceptible to disruption by other immune cells or neutralizing their harmful effects.

Intravenous Immunoglobulin Market Trends

• The IV immunoglobulin market is witnessing a clear shift in therapeutic applications, with its use extending beyond primary immunodeficiency disorders. Growing clinical acceptance in autoimmune and neurological diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome, and myasthenia gravis, has helped extend the market base.
   
• For example, in December 2025, the U.S. Food and Drug Administration (FDA) approved Amgen’s UPLIZNA (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive.
   
• These expanding therapeutic approvals and rising clinical adoption in immune-mediated neurological disorders highlight the evolving role of immunoglobulin-based therapies in modern treatment regimens.
   
• Furthermore, to address the growing worldwide demand, leading players are expanding plasma collection and fractionation capacity at a fast pace. The reliance on human plasma has spurred investments in donor centers, cutting-edge plasmapheresis equipment, and regional plasma sourcing models.
   
• For instance, in December 2022, CSL unveiled plasma manufacturing in Australia with the opening of its Plasma Fractionation Facility in Victoria. The new state-of-the-art facility allows CSL's manufacturing site to process up to 9.2 million plasma equivalent liters per annum. This is a nine-fold increase on current capacity for the site and will help meet the increasing demand for plasma-based, life-saving therapies for patients around the world.
   
• Firms are also entering into partnerships with local governments and health authorities to provide supply chain stability and mitigate geographic bottlenecks.
   
• Emerging markets are increasingly contributing to shaping the future of the IV immunoglobulin market. Asia-Pacific, Latin America, and Middle Eastern countries are experiencing stronger demand as healthcare expenditure increases, diagnosis rates rise, and specialty biologic access improves.
   

Intravenous Immunoglobulin Market Analysis

The global IV immunoglobulin market was valued at USD 10.8 billion and USD 11.8 billion in 2022 and 2023, respectively. The market size reached USD 13.3 billion in 2025, growing from USD 12.5 billion in 2024.
 

Based on the product type, the IV immunoglobulin market is segmented into IgG, IgA, IgM, IgD, and IgE. The IgG segment dominated the market with a market share of 71.1% in 2025. IgG is the largest-selling immunoglobulin, attributed to its broad clinical acceptance. The segment is expected to exceed USD 18.1 billion by 2035, growing at a CAGR of 6.7% during the forecast period.
 

• IgG constitutes the largest percentage of overall immunoglobulin concentration in circulation and plays a key role in immune defense; hence, it is the most prevalent class used in primary and secondary immunodeficiency conditions.
   
• IgG products benefit from a steady demand in various specialties like immunology, neurology, hematology, and internal medicine, thus supporting their strong market position.
   
• Apart from its clinical adaptability, the well-established regulatory and manufacturing procedures for IgG products have also reinforced the segment's market position.
   
• On the other hand, the IgA segment is expected to grow with a CAGR of 7.4%. IgA is witnessing rapid expansion in the global market for IV immunoglobulins, fueled mainly by its newly emerging function in mucosal immunity.
   

Based on the application, the intravenous immunoglobulin market is segmented into immunodeficiency diseases, chronic Inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, Guillain-Barré syndrome, and other applications. The immunodeficiency disease segment accounted for the highest market share of 32.8% in 2025 and is anticipated to grow at a CAGR of 6.9% over the analysis period. The segment is further categorized into primary immunodeficiencies (PID), secondary immunodeficiencies, hypogammaglobulinemia, and specific antibody deficiency.
 

• The immunodeficiency diseases segment is the major contributor to the IV immunoglobulin market because these conditions are chronic and lifelong, and IV immunoglobulin therapy has a pivotal role in their treatment.
   
• For example, individuals with PID are unable to generate adequate functional antibodies and are extremely susceptible to repeated, serious infections. Immunoglobulin replacement therapy is the mainstay of treatment and serves to augment immune function and decrease infection-related complications, hospitalizations, and mortality in these patients.
   
• In addition, patients with immunodeficiency diseases generally receive frequent infusions of immunoglobulin during their lifespan. This continuous therapy creates consistent demand.
   
• The chronic inflammatory demyelinating polyneuropathy (CIDP) segment stands at the second-largest position in the immunoglobulin market with a market share of 18.5% due to the proven efficacy of immunoglobulin treatment for this disabling neurologic disorder.
   
• Intravenous immunoglobulin is now a routine first-line therapy in CIDP, providing considerable clinical benefit through the modulation of the immune system and lessening nerve inflammation.
   
• Increased awareness and diagnosis of CIDP, in addition to its relapsing and chronic course, frequently requires extended treatment, further leading to constant demand for immunoglobulin products within this segment.
   

Based on the end use, the intravenous immunoglobulin market is segmented into hospitals and clinics, ambulatory surgical centers, homecare settings, and other end users. The hospitals and clinics segment accounted for the highest market share of 53.7% in 2025, owing to its function as the first point of care for immunoglobulin administration.
 

• Professional supervision, specialized apparatus, and controlled conditions are required for intravenous immunoglobulin (IVIg) therapy, all of which are present in hospitals and clinics.
   
• These healthcare institutions are optimally suited to handle probable infusion-related reactions, observe patient response in real-time, and deliver multidisciplinary management. Since immunoglobulin therapy is usually given over extended periods and involves repeated dosing, clinics and hospitals remain the most dependable and convenient routes of delivery.
   
• Clinics and hospitals also enjoy supportive reimbursement schemes for immunoglobulin therapy. National health programs as well as private insurance companies in most nations, now reimburse in-clinic IVIg infusions fully or partially, and hence these centers are made accessible to a larger group of patients.
   
• Hospitals also engage in clinical trials and research new uses for immunoglobulins. Their participation in such research usually leads to early uptake of newer immunoglobulin products, consolidating their market position even more.
   

North America Intravenous Immunoglobulin Market

North America dominated the global IV immunoglobulin market with the highest market share of 52.5% in 2025.
 

• North America holds a strong market position in the IV immunoglobulin market on account of its well-developed healthcare infrastructure, high prevalence of autoimmune and immunodeficiency diseases, and adequate reimbursement.
   
• A developed network of plasma collection facilities in the region facilitates an adequate supply of raw material for immunoglobulin manufacturing.
   
• Moreover, the presence of prominent pharmaceutical players, ongoing clinical research, and the early implementation of new treatment regimens also add to the maturity of the market.
   

The U.S. intravenous immunoglobulin market was valued at 5.3 billion and USD 5.7 billion in 2022 and 2023, respectively. In 2025, the market size reached USD 6.4 billion in 2025, growing from USD 6 billion in 2024.
 

• The U.S. has the highest global share of the IV immunoglobulin market due to its sophisticated healthcare infrastructure and high rate of plasma collection.
   
• The nation boasts one of the global leaders' plasma donation center networks, which provides a steady and active source of raw material used to make immunoglobulins. This local supply chain resilience provides the U.S. with a huge manufacturing and distribution advantage, providing for the continuous supply of intravenous (IVIg) immunoglobulin products throughout the country.
   
• The growing incidence of chronic and autoimmune diseases among the elderly population, together with high awareness rates and early diagnosis, has resulted in increasing numbers of patients on long-term immunoglobulin therapies. This propels stable and repeat demand for intravenous immunoglobulin therapies in the country.
   

Europe Intravenous Immunoglobulin Market

Europe intravenous immunoglobulin (IVIg) market accounted for USD 2.5 billion in 2025.
 

• Europe holds considerable market share in the IV immunoglobulin market due to robust public healthcare networks and an expanding patient base with immunological and neurological conditions.
   
• Several European countries have highly developed plasma collection networks, allowing widespread access to immunoglobulin therapy.
   
• Furthermore, Europe's emphasis on patient-centered care and favorable reimbursement policies drives the adoption of these therapies.
   

Germany has the largest market share in the European market for IV immunoglobulins, due to its highly developed healthcare infrastructure and established clinical practices for treating immunodeficiency and autoimmune diseases.
 

• The country has an excellent network of specialist hospitals and infusion units, which facilitate extensive use of intravenous immunoglobulin treatment.
   
• Secondly, Germany's strong plasma collection and fractionation capacity supports a stable local supply, thus minimizing import dependence and maintaining a uniform availability of immunoglobulin products for the treatment of acute as well as chronic diseases.
   

Asia Pacific Intravenous Immunoglobulin Market

The Asia Pacific region is poised for accelerated growth in the IV immunoglobulin market due to increasing awareness of immunological and neurological disorders, growing healthcare infrastructure, and rising healthcare spending in developing nations.
 

• Countries such as China, India, and South Korea are seeing increased demand for immunoglobulin therapy as diagnostic technology improves, and more instances of primary and secondary immunodeficiency disorders are diagnosed.
   
• Another key driver of growth in the Asia Pacific is the improvement in blood plasma collection and processing capacity. Nations are strategically investing in developing local plasma fractionation capacities to guarantee quality and safety.
   
• Meanwhile, government funding of rare disease treatment, improved insurance coverage, and growth in income levels are making expensive treatments such as immunoglobulins more affordable for larger patient bases.
   
• As healthcare infrastructure becomes more advanced and therapeutic quality converges closer to that of Western nations, the Asia Pacific region is set to emerge as one of the fastest-growing markets in the global IV immunoglobulin market.
   

China maintains the biggest market share among the Asia Pacific intravenous immunoglobulin market, fueled by its huge patient pool, growing number of cases of immunodeficiency and autoimmune diseases, and increasing availability of healthcare services.
 

• With a large number of patients suffering from chronic diseases necessitating treatment with immunoglobulins - e.g., primary immunodeficiencies, immune thrombocytopenia, and Kawasaki disease - the country has experienced continued growth in demand for intravenous immunoglobulins.
   
• Government-sponsored healthcare reforms and integration of immunoglobulin treatments into public insurance programs have further facilitated wider access and utilization in different provinces.
   

Latin America Intravenous Immunoglobulin Market

Latin America is growing as a highly potential region for the IV immunoglobulin market based on growing healthcare infrastructure and rising awareness of immune-related diseases.
 

• Brazil, Mexico, and Argentina are stepping up their diagnostic capabilities, resulting in higher rates of detection of primary immunodeficiencies, autoimmune diseases, and neurological diseases.
   
• As more national healthcare systems start to include advanced biologic therapies in their coverage, more patients are accessing intravenous immunoglobulin therapy, fueling the market.
   

Middle East & Africa Intravenous Immunoglobulin Market

The Middle East and Africa region is anticipated to witness steady growth in the IV immunoglobulin market, driven by rapid advancements in healthcare infrastructure and growing awareness of immune disorders.
 

• Countries such as Saudi Arabia, UAE, and South Africa are among the nations that have invested in high-quality diagnostic equipment and specialty treatment facilities, making it possible to identify and treat primary and secondary immunodeficiency diseases more effectively.
   
• With expanding economies and healthcare priorities moving toward chronic and rare diseases, MEA has the potential to become a dynamic market for the use of IV immunoglobulin in the next few years.
   

Intravenous Immunoglobulin Market Share

Leading companies like CSL Behring, Grifols SA, Kedrion Biopharma, Octapharma, and Takeda Pharmaceutical Company together hold approximately 55% of the market share in the consolidated global IV immunoglobulin market. These businesses keep their dominance by combining strong product lines, business alliances, legal clearances, and ongoing innovation. CSL holds a strong competitive advantage owing to its expertise in plasma collection and fractionation, which enables consistent supply and product quality, strengthening its leadership in the immunoglobulin segment.
 

In addition to the key players, new entrants are now shaping the market, notably in geographies such as Asia-Pacific and Latin America. Vendors like ADMA Biologics in the U.S. are finding success by streamlining processes and targeting niche indications. Other regional companies are looking at recombinant technologies or other production systems to decrease dependency on plasma-derived sources. These new players do not yet equal the size of global giants, but their innovative strategies and regional expansions hold the key to changing the trend toward larger competition and diversification in technology in the IV immunoglobulin market.

Intravenous Immunoglobulin Market Companies

Prominent players operating in the intravenous immunoglobulin industry are as mentioned below:

• ADMA Biologics
• Baxter International
• Biotest
• CSL Behring
• China Biologics Products
• Grifols SA
• Intas Pharmaceuticals
• Kedrion Biopharma
• LFB Biotechnologies
• Omrix Biopharmaceuticals (Johnson & Johnson)
• Octapharma AG
• Pfizer
• Shanghai RAAS Blood Products
• Takeda Pharmaceutical Company
   
• CSL Behring

CSL Behring is the leading player in the IV immunoglobulin market, supported by its broad understanding of plasma-derived therapies and an established international network. With an extensive network of plasma plasmapheresis centers and sophisticated manufacturing facilities, the company delivers a consistent supply and quality. CSL Behring's lead IVIg product, Privigen have broad applications in the treatment of immunodeficiency and neurological disorders, solidifying its leadership.
 

• Grifols SA

Grifols SA has established a strong presence in the market for IV immunoglobulins through extensive global reach. The firm maintains one of the world's largest networks of plasma collections that drives its manufacturing of immunoglobulin products. Grifols' continued emphasis on innovation and growth—such as new plants and expansion into up-and-coming markets—has enabled it to grow cost-effectively and meet changing healthcare requirements. Its strategic acquisitions and collaborations also continue to strengthen its competitiveness and worldwide reach in the immunoglobulin space.
 

Intravenous Immunoglobulin Industry News

• In June 2024, Grifols announced that Biotest, a Grifols Group company, received approval from the U.S. Food and Drug Administration (FDA) for Yimmugo, an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary immunodeficiencies (PID). This helped the company expand its product range.
   
• In February 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) approved the supplementary Biologics Licence Application (sBLA) for PANZYGA, an IVIg to treat adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological condition affecting the peripheral nerves.
   
• In January 2023, Eisai Co., Ltd., and Biogen announced that the FDA had authorized lecanemab-irmb (LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) for the treatment of Alzheimer's disease (AD).
   

The intravenous immunoglobulin market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• IgG
• IgA
• IgM
• IgD
• IgE

Market, By Application

• Immunodeficiency diseases
  • Primary immunodeficiencies
  • Secondary immunodeficiencies
  • Hypogammaglobulinemia
  • Specific antibody deficiency
• Chronic Inflammatory demyelinating polyneuropathy (CIDP)
• Myasthenia gravis   
• Multifocal motor neuropathy         
• Idiopathic thrombocytopenic purpura (ITP)        
• Inflammatory myopathies  
• Guillain-Barré syndrome    
• Other applications    

Market, By End Use

• Hospitals and clinics
• Ambulatory surgical centers
• Homecare settings
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE